MoneyWorks4Me

Kabra Drugs - Quaterly Results

14 Aug 2025 Evaluate
The revenue for the June 2025 quarter is pegged at Rs. 71.50 millions against Rs. 0.00 millions recorded during the year-ago period.The Net Loss for the quarter ended June 2025 is Rs. -5.00 millions as compared to Net Loss of Rs. -5.46 millions of corresponding quarter ended June 2024 Operating profit Margin for the quarter ended June 2025 improved to -4.97% as compared to -5.46% of corresponding quarter ended June 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 71.50 0.00 0.00 71.50 0.00 0.00 0.00 0.00 0.00
Other Income 0.16 0.00 0.00 0.16 0.00 0.00 6.40 0.00 0.00
PBIDT -4.97 -5.46 -8.97 -4.97 -5.46 -8.97 -10.78 -7.36 46.47
Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PBDT -4.97 -5.46 -8.97 -4.97 -5.46 -8.97 -10.78 -7.36 46.47
Depreciation 0.03 0.00 0.00 0.03 0.00 0.00 0.07 0.00 0.00
PBT -5.00 -5.46 -8.42 -5.00 -5.46 -8.42 -10.85 -7.36 47.42
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00
PAT -5.00 -5.46 -8.42 -5.00 -5.46 -8.42 -10.86 -7.36 47.55
Equity 237.08 43.89 440.17 237.08 43.89 440.17 237.08 43.89 440.17
PBIDTM(%) -6.95 0.00 0.00 -6.95 0.00 0.00 0.00 0.00 0.00
Peers
Company Name CMP
Sun Pharma. Inds. 1840.00
Dr. Reddys Labs. 1222.50
Cipla 1388.90
Lupin 2061.85
Zydus Lifesciences 1212.00
View more..